Exelixis enters the post-earnings stretch with a clean beat behind it, a $750 million buyback in hand, and a fresh pipeline catalyst — yet short sellers have quietly added to their positions all month, setting up a genuine tug-of-war between the bulls and the bears.
The company reported Q1 adjusted EPS of $0.87, well above the $0.70 consensus, on sales of $610.8 million that nudged past estimates. Management affirmed full-year 2026 revenue guidance of $2.525–$2.625 billion and simultaneously initiated the Stellar-201 Phase 2 trial of zanzalintinib in recurrent meningioma — broadening the drug's clinical story beyond its core colorectal franchise. The $750 million buyback authorisation added another layer of confidence to the release. The stock closed at $44.42 on May 5, up about 0.6% on the day, though it remains roughly 1.1% lower over the past week — suggesting the market is still digesting what the numbers actually mean for the longer-term growth debate.
Short positioning tells a story that runs directly against the bullish earnings narrative. At roughly 14% of free float, short interest is at its highest level in the 30-day window and has climbed about 9.7% over the past month — a meaningful build into results, not a retreat from them. The official FINRA figure puts days-to-cover at 13.1, a high reading that reflects both the size of the short book and the stock's relatively thin average daily volume. One notable feature of the lending market is that availability remains very loose — with cost-to-borrow running at just 0.41% (down 17% on the week) and borrow conditions easy, there is no sign of a squeeze building despite the elevated SI level. Bears are not scrambling for stock; they have plenty of room to hold or extend. The ORTEX short score of 63.3, broadly stable across the past fortnight, suggests the short thesis has not accelerated post-print but has not been abandoned either.
Options positioning has turned more defensive in a single session. The put/call ratio hit 0.87 on May 5, more than two standard deviations above its 20-day mean of 0.69 — the most protective reading in weeks. That single-day jump from 0.61 the prior session is notable; it suggests traders quickly re-hedged after the print rather than adding directional call exposure into strength. At 0.87 the ratio remains well below the 52-week high of 1.81, so this is a shift in tone rather than outright alarm, but it reinforces the sense that conviction on the upside is limited despite the beat.
The Street's response to results has been uniform in direction but cautious in degree. Morgan Stanley raised its target from $49 to $50 while keeping an Equal-Weight rating; Stifel moved from $44 to $47 on a Hold; Wells Fargo lifted from $35 to $40, also on Equal-Weight. All three actions landed today, and all three are neutral ratings. No firm upgraded on the back of the beat. The mean analyst target now sits at $48.82, roughly 10% above current price — a modest implied upside that aligns with the Street's collective scepticism. The bear case centres on generic erosion risk for Cabometyx, tolerability questions around zanzalintinib, and potential dilution. The bull case acknowledges the strong balance sheet and sustainable profitability, but frames positive conviction as conditional on pipeline execution. At a P/E of 12.2x and EV/EBITDA of 8.9x, valuation is not demanding — the P/E has compressed roughly 0.2x over 30 days — yet the Street appears content to wait for pipeline catalysts before upgrading.
Insider activity from February adds texture. A cluster of executive sales came in around $43.50–$44.50 — strikingly close to the current price — including the CFO, the Chief Scientific Officer, and several directors. Over the 90-day window, net insider sales totalled roughly $57.9 million. These were likely pre-planned transactions, and the share price has barely moved since, but the absence of any buying into what management was simultaneously describing as a strong growth story is worth noting.
The next confirmed earnings event is scheduled for May 26. Between now and then, the key variables to watch are whether the zanzalintinib Phase 2 initiation draws incremental trial data interest, whether short interest continues its month-long rebuild, and whether any bellwether firm steps up to an outright Buy rating — something none has yet done.
See the live data behind this article on ORTEX.
Open EXEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
